Aldeyra Therapeutics Competitors

Aldeyra Therapeutics (NASDAQ:ALDX) and Taro Pharmaceutical Industries (NYSE:TARO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Profitability

This table compares Aldeyra Therapeutics and Taro Pharmaceutical Industries' net margins, return on equity and return on assets.

Insider & Institutional Ownership

61.3% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 11.2% of Taro Pharmaceutical Industries shares are owned by institutional investors. 15.0% of Aldeyra Therapeutics shares are owned by insiders. Comparatively, 13.8% of Taro Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Aldeyra Therapeutics and Taro Pharmaceutical Industries, as provided by MarketBeat.

Aldeyra Therapeutics presently has a consensus price target of $26.1818, suggesting a potential upside of 109.79%. Taro Pharmaceutical Industries has a consensus price target of $81.00, suggesting a potential upside of 12.28%. Given Aldeyra Therapeutics' higher probable upside, equities research analysts clearly believe Aldeyra Therapeutics is more favorable than Taro Pharmaceutical Industries.

Valuation & Earnings

This table compares Aldeyra Therapeutics and Taro Pharmaceutical Industries' top-line revenue, earnings per share (EPS) and valuation.

Taro Pharmaceutical Industries has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Aldeyra Therapeutics has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. Comparatively, Taro Pharmaceutical Industries has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.

Summary

Aldeyra Therapeutics beats Taro Pharmaceutical Industries on 7 of the 13 factors compared between the two stocks.

Aldeyra Therapeutics (NASDAQ:ALDX) and Insmed (NASDAQ:INSM) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Valuation & Earnings

This table compares Aldeyra Therapeutics and Insmed's top-line revenue, earnings per share (EPS) and valuation.

Aldeyra Therapeutics has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aldeyra Therapeutics and Insmed's net margins, return on equity and return on assets.

Insider & Institutional Ownership

61.3% of Aldeyra Therapeutics shares are owned by institutional investors. 15.0% of Aldeyra Therapeutics shares are owned by insiders. Comparatively, 4.6% of Insmed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Aldeyra Therapeutics and Insmed, as provided by MarketBeat.

Aldeyra Therapeutics presently has a consensus price target of $26.1818, suggesting a potential upside of 109.79%. Insmed has a consensus price target of $53.5714, suggesting a potential upside of 102.46%. Given Aldeyra Therapeutics' higher probable upside, equities research analysts clearly believe Aldeyra Therapeutics is more favorable than Insmed.

Volatility & Risk

Aldeyra Therapeutics has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. Comparatively, Insmed has a beta of 2.43, suggesting that its stock price is 143% more volatile than the S&P 500.

Summary

Aldeyra Therapeutics beats Insmed on 9 of the 13 factors compared between the two stocks.

Aldeyra Therapeutics (NASDAQ:ALDX) and Pacira BioSciences (NASDAQ:PCRX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Valuation and Earnings

This table compares Aldeyra Therapeutics and Pacira BioSciences' top-line revenue, earnings per share (EPS) and valuation.

Pacira BioSciences has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aldeyra Therapeutics and Pacira BioSciences' net margins, return on equity and return on assets.

Insider and Institutional Ownership

61.3% of Aldeyra Therapeutics shares are held by institutional investors. 15.0% of Aldeyra Therapeutics shares are held by insiders. Comparatively, 5.8% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for Aldeyra Therapeutics and Pacira BioSciences, as provided by MarketBeat.

Aldeyra Therapeutics currently has a consensus price target of $26.1818, suggesting a potential upside of 109.79%. Pacira BioSciences has a consensus price target of $78.5833, suggesting a potential upside of 26.79%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Pacira BioSciences.

Volatility & Risk

Aldeyra Therapeutics has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500.

Summary

Pacira BioSciences beats Aldeyra Therapeutics on 7 of the 13 factors compared between the two stocks.

Aldeyra Therapeutics (NASDAQ:ALDX) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, dividends, profitability, risk and analyst recommendations.

Volatility & Risk

Aldeyra Therapeutics has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.

Insider and Institutional Ownership

61.3% of Aldeyra Therapeutics shares are held by institutional investors. 15.0% of Aldeyra Therapeutics shares are held by insiders. Comparatively, 7.0% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Aldeyra Therapeutics and PTC Therapeutics' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Aldeyra Therapeutics and PTC Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Aldeyra Therapeutics has higher earnings, but lower revenue than PTC Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for Aldeyra Therapeutics and PTC Therapeutics, as provided by MarketBeat.

Aldeyra Therapeutics currently has a consensus price target of $26.1818, suggesting a potential upside of 109.79%. PTC Therapeutics has a consensus price target of $65.10, suggesting a potential upside of 70.02%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aldeyra Therapeutics is more favorable than PTC Therapeutics.

Summary

Aldeyra Therapeutics beats PTC Therapeutics on 10 of the 13 factors compared between the two stocks.

MorphoSys (NASDAQ:MOR) and Aldeyra Therapeutics (NASDAQ:ALDX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for MorphoSys and Aldeyra Therapeutics, as reported by MarketBeat.

Aldeyra Therapeutics has a consensus target price of $26.1818, suggesting a potential upside of 109.79%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aldeyra Therapeutics is more favorable than MorphoSys.

Volatility & Risk

MorphoSys has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500.

Profitability

This table compares MorphoSys and Aldeyra Therapeutics' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares MorphoSys and Aldeyra Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Aldeyra Therapeutics has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

3.1% of MorphoSys shares are held by institutional investors. Comparatively, 61.3% of Aldeyra Therapeutics shares are held by institutional investors. 15.0% of Aldeyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Aldeyra Therapeutics beats MorphoSys on 7 of the 13 factors compared between the two stocks.

Rocket Pharmaceuticals (NASDAQ:RCKT) and Aldeyra Therapeutics (NASDAQ:ALDX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares Rocket Pharmaceuticals and Aldeyra Therapeutics' revenue, earnings per share and valuation.

Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Rocket Pharmaceuticals has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500.

Profitability

This table compares Rocket Pharmaceuticals and Aldeyra Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current recommendations for Rocket Pharmaceuticals and Aldeyra Therapeutics, as provided by MarketBeat.

Rocket Pharmaceuticals presently has a consensus price target of $59.1818, indicating a potential upside of 42.23%. Aldeyra Therapeutics has a consensus price target of $26.1818, indicating a potential upside of 109.79%. Given Aldeyra Therapeutics' higher possible upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Rocket Pharmaceuticals.

Insider and Institutional Ownership

61.3% of Aldeyra Therapeutics shares are owned by institutional investors. 41.4% of Rocket Pharmaceuticals shares are owned by company insiders. Comparatively, 15.0% of Aldeyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Rocket Pharmaceuticals beats Aldeyra Therapeutics on 7 of the 11 factors compared between the two stocks.